Patient characteristics of childhood AML patients (n = 109) for whom data on karyotyping or molecular genetics and cellular drug resistance were available
| . | All patients . | t(8;21) . | inv(16) . | t(15;17) . | Normal karyotype . | Abnormalities 5/7 . | t(9;11) . | Other 11q23 translocations . | Single random abnormality . | Multiple abnormalities . | Trisomy 8 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | 109 | 11 | 10 | 3 | 27 | 8 | 9 | 8* | 12 | 8 | 4 |
| Median age, y (P25-75) | 7.2 (2.8-12.1) | 10.9 (7.0-14.0) | 7.6 (4.6-11.7) | 13.3 (10.1-14.7)† | 10.5 (5.8-13.0) | 9.9 (5.2-10.5) | 3.7 (2.0-6.1) | 7.1 (5.6-10.2) | 3.5 (2.2-6.2) | 11.9 (3.5-14.0) | 13.5 (9.3-15.3)† |
| Sex; M, F | 60, 49 | 6, 5 | 5, 5 | 2, 1 | 10, 17 | 5, 3 | 3, 6 | 6, 2 | 9, 3 | 5, 3 | 3, 1 |
| Median WBC, ×109/L (P25-75) | 35.2 (12.5-81.5) | 20.2 (9.0-29.9) | 53.0 (36.7-67.9) | 6.8 (3.4-22.5)† | 24.9 (15.5-70.0) | 62.7 (18.7-88.5) | 14.4 (6.6-170.4) | 130.2 (59.7-173.2) | 41.4 (24.8-122.9) | 33.5 (11.5-92.6) | 82.5 (56.7-123.1)† |
| FAB | |||||||||||
| M0 | 5 | — | — | — | 1 | 1 | — | 1 | — | 1 | — |
| M1 | 12 | 1 | — | — | 4 | 2 | — | — | 2 | 1 | 2 |
| M2 | 27 | 9 | — | — | 9 | 3 | — | — | 2 | 4 | — |
| M3 | 4 | — | — | 3 | 1 | — | — | — | — | — | — |
| M4 (M4Eo) | 31 (13) | 1 (0) | 10 (8) | — | 8 (4) | 2 (0) | 1 (0) | 2 (0) | 5 (1) | — | 1 (0) |
| M5 | 21 | — | — | — | 2 | — | 8 | 5 | 2 | 2 | 1 |
| M6 | 1 | — | — | — | 1 | — | — | — | — | — | — |
| M7 | 6 | — | — | — | — | — | — | — | — | — | — |
| RAEB-t | 2 | — | — | — | 1 | — | — | — | 1 | — | — |
| Median CCS (P25-75) | 101 (80-128) | 94 (80-120) | 104 (88-118) | 107 (92-138)† | 100 (71-134) | 89 (71-117) | 83 (69-114) | 117 (86-125) | 100 (86-120) | 115 (70-158) | 94 (79-113)† |
| Median OD per 105 cells (P25-75) | 0.50 (0.37-0.65) | 0.46 (0.30-0.51) | 0.71 (0.61-0.81) | 0.47 (0.43-0.52)† | 0.54 (0.35-0.70) | 0.48 (0.29-0.49) | 0.45 (0.41-0.56) | 0.55 (0.32-0.86) | 0.45 (0.42-0.63) | 0.36 (0.35-0.39) | 0.26 (0.16-0.37)† |
| . | All patients . | t(8;21) . | inv(16) . | t(15;17) . | Normal karyotype . | Abnormalities 5/7 . | t(9;11) . | Other 11q23 translocations . | Single random abnormality . | Multiple abnormalities . | Trisomy 8 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | 109 | 11 | 10 | 3 | 27 | 8 | 9 | 8* | 12 | 8 | 4 |
| Median age, y (P25-75) | 7.2 (2.8-12.1) | 10.9 (7.0-14.0) | 7.6 (4.6-11.7) | 13.3 (10.1-14.7)† | 10.5 (5.8-13.0) | 9.9 (5.2-10.5) | 3.7 (2.0-6.1) | 7.1 (5.6-10.2) | 3.5 (2.2-6.2) | 11.9 (3.5-14.0) | 13.5 (9.3-15.3)† |
| Sex; M, F | 60, 49 | 6, 5 | 5, 5 | 2, 1 | 10, 17 | 5, 3 | 3, 6 | 6, 2 | 9, 3 | 5, 3 | 3, 1 |
| Median WBC, ×109/L (P25-75) | 35.2 (12.5-81.5) | 20.2 (9.0-29.9) | 53.0 (36.7-67.9) | 6.8 (3.4-22.5)† | 24.9 (15.5-70.0) | 62.7 (18.7-88.5) | 14.4 (6.6-170.4) | 130.2 (59.7-173.2) | 41.4 (24.8-122.9) | 33.5 (11.5-92.6) | 82.5 (56.7-123.1)† |
| FAB | |||||||||||
| M0 | 5 | — | — | — | 1 | 1 | — | 1 | — | 1 | — |
| M1 | 12 | 1 | — | — | 4 | 2 | — | — | 2 | 1 | 2 |
| M2 | 27 | 9 | — | — | 9 | 3 | — | — | 2 | 4 | — |
| M3 | 4 | — | — | 3 | 1 | — | — | — | — | — | — |
| M4 (M4Eo) | 31 (13) | 1 (0) | 10 (8) | — | 8 (4) | 2 (0) | 1 (0) | 2 (0) | 5 (1) | — | 1 (0) |
| M5 | 21 | — | — | — | 2 | — | 8 | 5 | 2 | 2 | 1 |
| M6 | 1 | — | — | — | 1 | — | — | — | — | — | — |
| M7 | 6 | — | — | — | — | — | — | — | — | — | — |
| RAEB-t | 2 | — | — | — | 1 | — | — | — | 1 | — | — |
| Median CCS (P25-75) | 101 (80-128) | 94 (80-120) | 104 (88-118) | 107 (92-138)† | 100 (71-134) | 89 (71-117) | 83 (69-114) | 117 (86-125) | 100 (86-120) | 115 (70-158) | 94 (79-113)† |
| Median OD per 105 cells (P25-75) | 0.50 (0.37-0.65) | 0.46 (0.30-0.51) | 0.71 (0.61-0.81) | 0.47 (0.43-0.52)† | 0.54 (0.35-0.70) | 0.48 (0.29-0.49) | 0.45 (0.41-0.56) | 0.55 (0.32-0.86) | 0.45 (0.42-0.63) | 0.36 (0.35-0.39) | 0.26 (0.16-0.37)† |
The clinical data of specific genetic subgroups are given. Two patients with MLL rearrangements, but without identified translocation partner chromosome, were excluded in the subgroup of other 11q23 abnormalities, while 7 Down syndrome AML patients have been reported elsewhere.
Characteristics of the MTT assay are shown for each genetic subgroup—that is, CCS after 4 days of culture and the OD per 105 cells. For statistical analysis, see “Results.”
P25-75, 25th and 75th percentile; WBC indicates white blood cell count; FAB, French-American-British morphology classification; RAEB-t, refractory anemia in excess of blasts in transformation; CCS, control cell survival after 4 days of culture; OD, optical density.
Translocation partners were t(4;11), n = 2; t(6;11), n = 3; t(10;11), n = 2; t(11;17), n = 1.
The range is given instead of P25-75.